Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2024-10-24 Earnings Release
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Earnings Release Classification · 100% confidence The document is explicitly titled '# **Press Release**' and details positive Phase 3 clinical trial data for Dupixent in chronic spontaneous urticaria (CSU), including statistical results, safety profiles, and future regulatory plans ('Confirmatory data to support US regulatory resubmission by year-end'). This format—a formal announcement of recent developments, trial results, and corporate updates, often released before a full financial report—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on clinical trial results and regulatory milestones rather than comprehensive quarterly financials (which would suggest IR or 10-K), and it is a direct announcement of results rather than a presentation (IP) or a transcript (CT), the most fitting category is Earnings Release (ER), as these often accompany or precede quarterly financial reporting periods to highlight key operational achievements. It is not a short announcement linking to a report, so RPA/RNS is less appropriate than ER. Q4 2024
2024-10-24 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references press releases attached as exhibits and does not contain detailed financial statements or substantive financial data. The document is short (1452 characters) and primarily serves as a regulatory filing to inform about recent press releases. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. According to the rules, such filings are best classified as Regulatory Filings (RNS).
2024-10-21 English
Communiqué de presse : Sanofi et CD&R s’allient pour soutenir les ambitions d’Opella dans la santé grand public
M&A Activity Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces a major corporate transaction: Sanofi entering into exclusive negotiations with CD&R to transfer a 50% controlling stake in its consumer healthcare division, Opella. It details the valuation, the impact on Sanofi's financial reporting (classifying Opella as discontinued operations), and provides updated financial outlooks (BNPA forecasts). This type of announcement, detailing a significant corporate action like a joint venture or divestiture, is best classified as a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were purely a mandatory disclosure. However, since it explicitly discusses the structure of the deal, valuation, and capital allocation implications (return to shareholders), 'CAP' is the most specific fit among the provided options for a major transaction announcement. It is not a full 10-K, an earnings release (ER), or a management discussion (MDA) of periodic results, but rather a strategic transaction announcement.
2024-10-21 French
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
M&A Activity Classification · 99% confidence The document is explicitly titled "Press Release" and announces a major corporate transaction: Sanofi entering exclusive negotiations to sell a 50% stake in its consumer healthcare business, Opella, to CD&R. It discusses financial guidance updates, accounting treatment (discontinued operations), and transaction details (valuation, expected closing Q2 2025). This type of announcement, detailing significant corporate actions, financing implications, and strategic shifts, is characteristic of a major corporate event announcement. While it touches upon financial results (EPS guidance upgrade), the primary focus is the M&A/Capital structure change. Since there is no specific code for a general M&A announcement that isn't a tender offer (TAR), and this document is a formal announcement of a major transaction involving capital structure and strategic focus, it aligns best with Capital/Financing Update (CAP) or potentially M&A Activity (TAR). Given the core of the news is the sale/partnership structure (a form of financing/capital restructuring), CAP is a strong fit. However, the transaction is explicitly a sale of a controlling stake, which falls under M&A. Since TAR is defined as 'Merger proposals or takeover bids,' and this is a sale/joint venture, TAR is the most precise fit for a major transaction announcement of this nature. It is not an Earnings Release (ER) as it's not primarily focused on Q3 results, nor is it a full Annual Report (10-K) or Interim Report (IR). It is a strategic corporate announcement.
2024-10-21 English
Communiqué de presse : Sanofi et Orano Med unissent leurs forces pour développer des radiothérapies internes vectorisées de nouvelle génération
Regulatory Filings Classification · 90% confidence The document is a press release dated October 17, 2024, announcing a strategic agreement between Sanofi and Orano Med regarding the development of next-generation radiotherapies. It details the collaboration, quotes executives, outlines financial considerations (Sanofi investing €300 million for a 16% stake), and includes standard 'About Us' sections and forward-looking statements typical of corporate news releases. This content is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific announcement about a strategic partnership and investment, which falls under general corporate news. Since there is no specific category for 'Strategic Partnership Announcement,' and it is a formal press release detailing business developments, the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general regulatory/corporate announcement, or potentially 'Capital/Financing Update' (CAP) due to the explicit mention of a €300 million investment. However, the primary focus is the scientific collaboration and partnership, making it a general corporate announcement. Given the options, RNS is the best fit for a general corporate press release that doesn't fit a more specific financial or reporting category, although CAP is a strong secondary candidate due to the investment detail. I will classify it as RNS as it is a broad corporate announcement.
2024-10-17 French
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
Regulatory Filings Classification · 98% confidence The document is a press release dated October 17, 2024, announcing a strategic agreement between Sanofi and Orano Med regarding the development of radioligand medicines. It details the partnership, quotes executives, outlines financial considerations (€300 million equity investment), and includes standard boilerplate sections like 'About Sanofi' and 'Sanofi forward-looking statements'. This format is characteristic of a corporate announcement regarding a significant business event, such as a partnership or investment, which falls under the scope of a general corporate filing or news release. Since it is not a formal regulatory report (like 10-K, AR, or IR), nor a specific announcement like a dividend (DIV) or management change (MANG), the most appropriate classification is the general regulatory announcement/news release category, RNS, as it communicates material, non-periodic information to the market.
2024-10-17 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.